Prospective Study: The Effect on Clinical Outcome After Treatment of MTP Cartilage Lesions in Hallux Valgus Surgery

Condition(s) studied

Investigational drug(s) / intervention(s)

Debridement of the MTP1 cartillage lesion and microfracture: Patients with a MTP1 cartillage lesion \> grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture

Study summary

The aim of this study is to investigate the point or nonsense of treating cartilage lesions at the level of the first metatarsophalane joint. To date, no clear guidelines have been found in the literature with regard to the treatment of cartilage lesions at the MTP I joint during corrective surgery for hallux valgus, nor has it been investigated whether this can have an effect on the clinical outcome.

Eligibility

Primary outcome measure(s)

• Change in AOFAS — 10 days, 5 weeks, 4 months, 1 year
  American Orthopaedic Foot and Ankle Society (AOFAS) score - combines a clinician-reported and a patient-reported part for measuring the outcome of treatment in patients who sustained a complex hindfoot injury based on pain, function and alignment: 0 (bad outcome) to 100 (very good outcome)
• Change in SF36 — 10 days, 5 weeks, 4 months, 1 year
  Short Form 36 (SF-36) Health Survey - consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
• Change in VAS pain — 10 days, 5 weeks, 4 months, 1 year
  Visual Analogue Scale pain score - 0 (no pain) to 10 (worse pain)

Trial sites (1)

Other trials for the same condition